BIOTIKA |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.8 EUR | -4.80% |
|
-1.65% | +9.17% |
| Apr. 25 | Biotika a.s. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Biotika a.s. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| Sales 2022 | 11.03M 11.79M | Sales 2023 | 23.28M 24.89M | Capitalization | 21.43M 22.92M |
|---|---|---|---|---|---|
| Net income 2022 | - 0 | Net income 2023 | - 0 | EV / Sales 2022 | 1.86 x |
| Net cash position 2022 | 2.14M 2.29M | Net cash position 2023 | 3.09M 3.3M | EV / Sales 2023 | 0.79 x |
| P/E ratio 2022 |
-19.6
x | P/E ratio 2023 |
-
| Employees | 198 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 18.24% |
More Fundamentals
* Assessed data
More news
| 1 day | -4.80% | ||
| 1 week | -1.65% | ||
| Current month | +2.59% | ||
| 1 month | +2.59% | ||
| 3 months | +3.48% | ||
| 6 months | +7.21% | ||
| Current year | +9.17% |
1 week
23.20
25.00
1 month
23.2025.00
Current year
22.4025.00
1 year
20.0025.00
3 years
20.0042.00
5 years
20.0042.00
10 years
18.0061.05
| Managers | Title | Age | Since |
|---|---|---|---|
Ján Dzúrik
DFI | Director of Finance/CFO | 43 | 05-12-31 |
Milan Zemko
CIO | Chief Investment Officer | - | - |
Ludmila Kovácová
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mária Kincešová
CHM | Chairman | - | 03-01-23 |
| Director/Board Member | - | 04-05-27 | |
Jozefína Gregová
BRD | Director/Board Member | - | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 100.00% | 0 M€ | -3.57% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 23.8 | -4.80% | 10 |
| 24-04-25 | 25 | +7.76% | 57 |
| 24-04-23 | 23.2 | -4.13% | 10 |
End-of-day quote Bratislava S.E., April 25, 2024
More quotes
Biotika as is a Slovakia-based joint stock company that specializes in biotechnology and production of pharmaceutical. The Company's activities are grouped into three main areas: biotechnological production of the substances of penicillin, chlorotetracycline and dextrans; production of final drug-forms for both human and veterinary use, including: penicillin and cephalosporin preparations, hormonal preparations, vitamin preparations; as well as production of premixes containing nutrition additives and medicated nutritive preparations. As of December 31, 2011, the Company operated two wholly owned subsidiaries, COV as Slovenska Lupca and Biotkika KLF as Slovenska Lupca.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +9.17% | 24.98M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- 1BSL01AE Stock
